JPMorgan Chase & Co. has significantly expanded its holdings in 3M Co. while adjusting price targets across various sectors, lowering its outlook for firms like A.O. Smith and Amcor, yet boosting targets for UnitedHealth Group to $420. The bank is eyeing a $105 billion growth in the GLP-1 drug market by the end of the decade and has labeled a selloff in AutoZone earnings as a buying opportunity. Additionally, JPMorgan is enhancing its fintech approach to attract younger clients and is deeply investing in blockchain technology as part of its broader strategic push into emerging financial markets.
“JPMorgan Chase & Co. · expands · holdings in 3M Co. · with significant stock acquisition”
“A.O. Smith · price target lowered to · JPMorgan · $65 from $75”
“JPMorgan · lowered the price target on Amcor · to $44 · from $50”
“JPMorgan · believes AutoZone earnings · selloff · is a buying opportunity”
“AutoZone · earnings selloff · a buying opportunity · according to JPMorgan”
“JPMorgan · lifted the price target on UnitedHealth Group Incorporated (NYSE:UNH) to · $420 · from $389”
“JP Morgan · expects the GLP-1 industry to swell to · $105 billion · by the end of the decade”
“JPMorgan Chase & Co. · projects that the broader obesity drug market could approach · $200 billion by 2030 · true”
“JPMorgan Chase & Co (NYSE:JPM) · is · one of the most undervalued blockchain stocks to buy now”
“Meta Platforms · is working with · Morgan Stanley and JPMorgan Chase & Co (NYSE:JPM) · on a financing package worth about $13 billion for a new data center in El Paso, Texas”
“JPMorgan · has built · significant blockchain infrastructure through its Kinexys unit”
“JPMorgan · is piloting · tokenization of traditional assets · such as government bonds and money market funds”
